The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma

Update on molecular findings in rhabdomyosarcoma

(2017) Dina El Demellawy et al.   PATHOLOGY

Early results from Children's Oncology Group (COG) ARST0431: Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS).

(2017) B. Weigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

(2016) Brenda J. Weigel et al.   JOURNAL OF CLINICAL ONCOLOGY

New insights into signalling-pathway alterations in rhabdomyosarcoma

(2014) B Zhu et al.   BRITISH JOURNAL OF CANCER

Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group

(2013) Brenda Weigel et al.   PEDIATRIC BLOOD & CANCER

Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft-tissue Sarcoma committee experience and rationale for current COG studies

(2012) Suman Malempati et al.   PEDIATRIC BLOOD & CANCER

Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

(2012) Douglas S. Hawkins et al.   PEDIATRIC BLOOD & CANCER

Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group

(2011) Suman Malempati et al.   JOURNAL OF CLINICAL ONCOLOGY

Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma

(2011) J. Abraham et al.   MOLECULAR CANCER THERAPEUTICS

Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study

(2010) Rochelle Bagatell et al.   JOURNAL OF CLINICAL ONCOLOGY

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

(2009) Carola A.S. Arndt et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups

(2008) Odile Oberlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

(2008) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER